![Nora Therapeutics Logo](/news-release/logo/311229/0/311229.jpg?lastModified=12%2F09%2F2016%2023%3A10%3A40&size=2)
Nora Therapeutics Appoints Joseph L. Turner to Board of Directors
July 08, 2015 08:00 ET
|
Nora Therapeutics
PALO ALTO, Calif., July 8, 2015 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address significant unmet needs in reproductive medicine, announced...
![Nora Therapeutics Logo](/news-release/logo/311229/0/311229.jpg?lastModified=12%2F09%2F2016%2023%3A10%3A40&size=2)
Nora Therapeutics to Present at Upcoming Conferences in December
November 26, 2014 13:30 ET
|
Nora Therapeutics
PALO ALTO, Calif., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that...
![Nora Therapeutics Logo](/news-release/logo/311229/0/311229.jpg?lastModified=12%2F09%2F2016%2023%3A10%3A40&size=2)
Nora Therapeutics Names Sandra Shpilberg Vice President, Strategic Marketing & Commercial Planning
September 16, 2014 16:00 ET
|
Nora Therapeutics
PALO ALTO, Calif., Sept. 16, 2014 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, today announced...
![Nora Therapeutics Logo](/news-release/logo/311229/0/311229.jpg?lastModified=12%2F09%2F2016%2023%3A10%3A40&size=2)
Nora Therapeutics Presents Phase 1 Data on NT100 at the European Society of Human Reproduction and Embryology Annual Meeting
June 30, 2014 07:30 ET
|
Nora Therapeutics
Results show NT100 was well-tolerated, no serious adverse events
Data suggest NT100 may support maternal-fetal tolerance, has potential to complement existing therapies to maximize pregnancy,...
![Nora Therapeutics Logo](/news-release/logo/311229/0/311229.jpg?lastModified=12%2F09%2F2016%2023%3A10%3A40&size=2)
Nora Therapeutics Announces Initiation of Phase 2 RESPONSE Research Study
June 26, 2014 07:30 ET
|
Nora Therapeutics
RESPONSE is Studying NT100 in Pregnant Women With Unexplained Recurrent Pregnancy Loss
PALO ALTO, Calif., June 26, 2014 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused...
![Nora Therapeutics Logo](/news-release/logo/311229/0/311229.jpg?lastModified=12%2F09%2F2016%2023%3A10%3A40&size=2)
Nora Therapeutics to Participate at Janney Capital Markets Boston Healthcare 1X1 Corporate Access Day
June 24, 2014 07:30 ET
|
Nora Therapeutics
PALO ALTO, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Nora Therapeutics, a biotechnology company focused on developing therapeutics to address unmet needs in reproductive medicine, announced today that...